L2M – Strategic Development of Protease-Resistant ADAMTS13 as a Therapeutic for Cardiovascular Disorders and Sepsis

This project aims to develop a novel therapeutic drug aimed at revolutionizing the treatment of severe cardiovascular diseases (CVD) and sepsis. Our project focuses on the modification of the ADAMTS13 protein, an enzyme that plays a crucial role in the blood clotting process. In patients with severe CVD or sepsis, ADAMTS13 is rapidly degraded, leading to an increased risk of life-threatening complications. Our solution is an injectable form of modified ADAMTS13, engineered to be resistant to degradation even in the most severe cases.
This project aligns with the Mitacs Business Strategy Internship (BSI) program’s objectives by bridging the gap between advanced scientific research and practical market application. We aim to validate and refine this therapeutic solution through extensive market research, prototype testing, and feedback integration from medical professionals. A key goal is to establish a clear pathway from laboratory research to real-world healthcare settings, addressing an unmet need in the treatment of severe CVD and sepsis.
Additionally, the project entails engagement with stakeholders and potential partners, leveraging networking opportunities provided by the Mitacs BSI program to foster collaborations essential for commercialization. Our third objective focuses on developing a scalable commercial strategy, including navigating regulatory pathways and understanding market dynamics.
This innovative project promises significant health benefits by providing a new, effective treatment for severe CVD and sepsis patients.

Faculty Supervisor:

Colin Kretz

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Life Sciences

Sector:

Pharmaceuticals; Health and Related Sciences & Technology; Biotechnology

University:

McMaster University

Program: